Traditional Chinese medicine monomer composition for antagonizing lung injury and its application

A monomer composition and lung injury technology, applied in the direction of drug combination, pharmaceutical formula, antiviral agent, etc., can solve the problems of severe infection of lung tissue, decreased phagocytosis, aggravation of lung tissue damage, etc., to achieve inhibition of pulmonary fibrosis, Inhibit EMT and promote cell repair effect

Active Publication Date: 2020-12-22
GUANGZHOU INST OF RESPIRATORY DISEASE +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the lung tissue of patients with cystic fibrosis, it was found that the NF-κB and MAPK signaling pathways in macrophages were overactivated, releasing more pro-inflammatory factors and chemokines, such as IP-10, IL-6, IL -8, MCP-1, MIP-1α, MIP-1β and RENTES, but aggravated the damage of lung tissue, leading to severe lung inflammation
Moreover, some studies have found that the phagocytosis of macrophages and neutrophils in the lung tissue of patients with cystic fibrosis is severely reduced, leading to severe lung tissue infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Traditional Chinese medicine monomer composition for antagonizing lung injury and its application
  • Traditional Chinese medicine monomer composition for antagonizing lung injury and its application
  • Traditional Chinese medicine monomer composition for antagonizing lung injury and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] The molar ratio between quercetin, glycyrrhizic acid and ferulic acid is 1:1:1, that is, the molar concentration of ferulic acid is 100 μM, the molar concentration of glycyrrhizic acid is 100 μM, and the molar concentration of quercetin is 100 μM. It is prepared into tablets with a pharmaceutically acceptable carrier through a conventional process.

Embodiment 2

[0059] The molar ratio between quercetin, glycyrrhizic acid and ferulic acid is 1:2:1. That is, the molar concentration of ferulic acid is 200 μM, the molar concentration of glycyrrhizic acid is 100 μM, and the molar concentration of quercetin is 100 μM. Prepare capsules with pharmaceutically acceptable carriers through conventional techniques.

Embodiment 3

[0061] The molar ratio between quercetin, glycyrrhizic acid and ferulic acid is 1:3:1. That is, the molar concentration of ferulic acid is 300 μM, the molar concentration of glycyrrhizic acid is 100 μM, and the molar concentration of quercetin is 100 μM. Prepared into microcapsules with pharmaceutically acceptable carriers through conventional techniques.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a traditional Chinese medicine monomer composition for antagonizing lung injury. The traditional Chinese medicine monomer composition comprises main active ingredients such asquercetin, glycyrrhizic acid and ferulic acid. The invention also discloses a use of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition can adjust the respiratory immune system through activating the cAMP-dependent CFTR, prevent the pathological damage caused by the excessive immune response caused by the loss or inhibition of the immune tolerance mechanism, inhibit the lung fibrosis and promote the repair of damaged cells into normal cells.

Description

technical field [0001] The invention relates to a medicine for resisting lung injury, in particular to a traditional Chinese medicine monomer composition for antagonizing lung injury. The present invention also relates to the application of the traditional Chinese medicine monomer composition. Background technique [0002] The respiratory innate immune system is the body's first line of defense against pathogenic microorganisms. Studies have shown that the body recognizes pathogen-associated molecular patterns (PAMPs) of pathogenic microorganisms through pattern recognition receptors (PRRs), initiates an innate immune response against pathogens, and recruits immune phagocytes to the lungs by releasing inflammatory factors, chemokines, etc. Eliminate invading pathogens inside and outside cells, this inflammatory process can cause tissue cell damage. At the same time, the body can also initiate the immune tolerance mechanism to control the degree of inflammatory response and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K31/704A61K31/192A61P1/00A61P31/16
CPCA61K31/192A61K31/352A61K31/704A61K2300/00
Inventor 曹珂付志萍郝建新徐军潘俊辉王鹏
Owner GUANGZHOU INST OF RESPIRATORY DISEASE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap